ClinicalTrials.gg
TerminatedNCT01092832Updated Jun 23, 2016Results posted

A Study Of The Safety, Tolerability And Effective Of Voriconazole For The Treatment Of Serious Candida Infection And Candida Infection Of The Throat In Pediatric Patients

A Phase 3 interventional study of voriconazole in Candidiasis, sponsored by Pfizer. Terminated at 14 sites in 8 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2016-06-23.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Why this study was terminated
This protocol terminated prematurely on July 8, 2013 due to slow enrollment, not because of any safety issues or concerns.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
23
Allocation
Non-randomized
Ages
2 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 15 studies in Candidiasis by Pfizer — none open to participants now, none under way, none of them phase 3. Candidiasis · Pfizer.

Enrollment
8th of 11
23 · median 41
Started
2010
the only one that year
Phase 3
6 of 15
none open now
Registered
13th of 15
by date

Among the 15 studies in Candidiasis by Pfizer, this one is the 8th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2010, is one of 6 in phase 3, and was the 13th registered.

Candidiasis

132 studies on the registry are indexed under Candidiasis; 9 are open to participants now.

Browse Candidiasis studies →

Open to participants now

None of the 15 studies in Candidiasis by Pfizer is open now. The open studies under Candidiasis, anywhere →

Who these studies take

Of the 6 Candidiasis studies recruiting now, 4 set no upper age limit and 2 stop at 75 or younger; 2 take children under 18; 3 take healthy volunteers.

This study: 2 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies in Candidiasis by Pfizer as a file.
02

Study summary

The purpose of this study is to determine whether voriconazole is safe and effective for the treatment of serious Candida infection and Candida infection of the esophagus in children and adolescents.

03

Conditions studied

  • Candidiasis

Browse trials for

Keywords

  • Invasive Candidiasis Candidemia Esophageal Candidiasis
04

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female 2 to \<18 years of age; Subjects 2 to \<12 years of age will be permitted to enroll in this study only after a Pfizer sponsored pharmacokinetic study confirms the proposed dosage corresponding to this age group is appropriate.
  • Patients with confirmed Candida infection of the blood, body tissues, or the esophagus.
  • Patient's doctor feels voriconazole is an appropriate choice of therapy.

Exclusion criteria

Exclusion Criteria:

  • A known allergy to voriconazole or to azole to antifungal drugs.
  • Females who are pregnant, lactating (breast feeding) or planning a pregnancy during the course of the study, or who are of and not using highly effective method of .
  • A patient who is receiving treatment with a drug know to interfere with the heart's electrical system ( prolongation).
  • A patient who is receiving treatment with a drug that is not permitted to be used with voriconazole.
  • For primary therapy: a patient who has received more than 48 hours of antifungal therapy for the current episode of Candida infection.
  • A patient with significant underlying liver disease at the time of enrollment in the study.
  • A patient with significant renal disease ( \< 50 ml/min) at the time of enrollment in the study.
  • A patient with a high likelihood of death within 72 hours of study enrollment due to factors unrelated to Candida infection.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    Active voriconazole

    All subjects in this study will receive active voriconazole in an open-label fashion; there is no comparator in this study.

    Drug: voriconazole

Interventions

  • Subjects 12 - \<18 yrs (excluding subjects 12 - 14 yrs weighing \<50kg): For IC, the loading dose is 6 mg/kg IV q12h on Day 1, followed by 4 mg/kg IV q12h thereafter. Oral therapy, if given, will be administered at a dose of 200 mg q12h. For EC, no loading dose is required, and subjects will be initiated on 3 mg/kg IV q12h. Oral therapy, if given, will be administered at a dose of 200 mg q12h. Subjects 2 - \<12 yrs, and subjects 12 - 14 weighing \<50kg: For IC, the loading dose is 9 mg/kg IV q12h on Day 1, followed by 8 mg/kg IV q12h thereafter. For EC, no loading dose is required, and subjects will be initiated on 4 mg/kg IV q12. Oral therapy, if given, will be administered at a dose of 9 mg/kg q12h (maximum initial dose of 300 mg). Subjects will be treated for a minimum of 14 days for invasive candidiasis/candidemia or a minimum of 7 days for esophageal candidiasis. Subjects will be treated for up to a maximum of 42 days.

    Also known as: Vfend

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Adverse Events - Overall Summary

    Percentage of participants with adverse events (AEs), serious adverse events (SAEs), severe AEs, who discontinued due to AEs, or who had dose redued or temporarily discontinued due to AEs.

    Time frame: Baseline up to 1 month follow-up

Secondary outcomes

  1. Percentage of Participants With a Global Response of Success at End of Treatment (EOT)

    Global response was determined programmatically based on investigator assessment of clinical and microbiological response. Global response of success was defined as clinical cure or improvement AND microbiological eradication or presumed eradication. Exact 95 percent (%) confidence interval for binomial proportions using Clopper-Pearson method.

    Time frame: EOT (from 7 to 42 days of treatment)

  2. All-Cause Mortality - Number of Participant Deaths

    Time frame: Day 28 and 1 Month Follow-up

  3. Time to Death

    Time frame: Baseline up to 1 month follow-up

07

Results

Posted Aug 17, 2015
Limitations and caveats
The study was prematurely terminated due to slow enrollment. The study was not terminated due to any safety issues or concerns. Interpretation of the data are limited due to the small sample size and descriptive design.

Participant flow

Participant flow — Overall Study
MilestoneVoriconazole: 2 to <12 YearsVoriconazole: 12 to <18 Years
Started148
Completed138
Not completed10
Withdrew: Other10

Outcome measures

PrimaryPercentage of Participants With Adverse Events - Overall Summary

Percentage of participants with adverse events (AEs), serious adverse events (SAEs), severe AEs, who discontinued due to AEs, or who had dose redued or temporarily discontinued due to AEs.

Time frame:
Baseline up to 1 month follow-up
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events - Overall Summary
percentage of participantsVoriconazole: 2 to <12 YearsVoriconazole: 12 to <18 Years
With AEs92.975.0
With SAEs14.312.5
With severe AEs28.637.5
Discontinued due to AEs14.325.0
Dose reduced/temporary discontinuation due to AE21.40
SecondaryPercentage of Participants With a Global Response of Success at End of Treatment (EOT)

Global response was determined programmatically based on investigator assessment of clinical and microbiological response. Global response of success was defined as clinical cure or improvement AND microbiological eradication or presumed eradication. Exact 95 percent (%) confidence interval for binomial proportions using Clopper-Pearson method.

Time frame:
EOT (from 7 to 42 days of treatment)
Reported as:
Number · percentage of participants
Percentage of Participants With a Global Response of Success at End of Treatment (EOT)
percentage of participantsVoriconazole: 2 to <12 YearsVoriconazole: 12 to <18 Years
Percentage of Participants With a Global Response of Success at End of Treatment (EOT)88.9 (51.75 to 99.72)62.5 (24.49 to 91.48)
SecondaryAll-Cause Mortality - Number of Participant Deaths
Time frame:
Day 28 and 1 Month Follow-up
Reported as:
Number · participants
All-Cause Mortality - Number of Participant Deaths
participantsVoriconazole: 2 to <12 YearsVoriconazole: 12 to <18 Years
Day 2800
1 Month Follow-up00
SecondaryTime to Death
Time frame:
Baseline up to 1 month follow-up

No measurements were reported for this outcome.

Adverse events

Collected over Day 1 up to Day 49 (7 days after the last dose of study drug). Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Voriconazole: 2 to <12 Years—2/14 (14.3%)13/14 (92.9%)
Voriconazole: 12 to <18 Years—1/8 (12.5%)6/8 (75%)
Most frequent serious events
Most frequent serious events
EventVoriconazole: 2 to <12 YearsVoriconazole: 12 to <18 Years
Splenic candidiasisInfections and infestations0/141/8
Febrile neutropeniaBlood and lymphatic system disorders1/140/8
PneumoniaInfections and infestations1/140/8
Most frequent other events
Showing 10 of 92
Most frequent other events
EventVoriconazole: 2 to <12 YearsVoriconazole: 12 to <18 Years
OesophagitisGastrointestinal disorders0/142/8
Alanine aminotransferase abnormalInvestigations3/140/8
RashSkin and subcutaneous tissue disorders3/140/8
PhotophobiaEye disorders2/141/8
HypothermiaGeneral disorders2/141/8
PyrexiaGeneral disorders2/141/8
Gamma-glutamyltransferase abnormalInvestigations2/140/8
HypokalaemiaMetabolism and nutrition disorders2/140/8
HypertensionVascular disorders2/140/8
HypothrombinaemiaBlood and lymphatic system disorders0/141/8

Baseline characteristics

Safety population: all participants who received at least 1 dose of study medication.

Age, Continuous
Age, Continuous(years)Voriconazole: 2 to <12 YearsVoriconazole: 12 to <18 YearsTotal
Mean6.8 ± 2.914.4 ± 1.79.5 ± 4.5
Sex: Female, Male
Sex: Female, Male(Participants)Voriconazole: 2 to <12 YearsVoriconazole: 12 to <18 YearsTotal
Female8614
Male628
08

Study locations

14 sites
  • Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology
    Wuhan, Hubei 430030, China
  • Beijing Children's Hospital, Capital University of Medical Sciences
    Beijing, 100045, China
  • Fakultni nemocnice Brno - Klinika detske onkologie
    Brno, 625 00, Czech Republic
  • Department of Paediatrics and Adolescent Medicine
    Hong Kong, 0, Hong Kong
  • Queen Mary Hospital
    Hong Kong, Hong Kong
  • The Chinese University of Hong Kong, Prince of Wales Hospital
    Shatin, N.T., Hong Kong
  • Semmelweis Egyetem, II. sz. Szemeszeti Klinika
    Budapest, 1085, Hungary
  • Semmelweis Egyetem, II. sz. Gyermekgyogyaszati Klinika
    Budapest, 1094, Hungary
  • Fovarosi Onkormanyzat Egyesitett Szent Istvan és Szent Laszlo Korhaz-Rendelointezet
    Budapest, 1097, Hungary
  • Instituto Nacional de Pediatria
    Colonia Insurgentes Cuicuilco, Delegacion Coyoacan, DF 04530, Mexico
  • Medical Research Laboratory Philippine General Hospital University of the Philippines
    Ermita,, Manila 1000, Philippines
  • Rm. 112 ICHHD, National Institutes of Health-University of the Philippines Manila
    Manila, 1000, Philippines
  • Oddzial Pediatryczny I- Hematologiczno-Onkologiczny
    Olsztyn, 10-561, Poland
  • Detska fakultna nemocnica s poliklinikou Bratislava
    Bratislava, 833 40, Slovakia
09

References and documents

Publications

  • Martin JM, Macias-Parra M, Mudry P, Conte U, Yan JL, Liu P, Capparella MR, Aram JA. Safety, Efficacy, and Exposure-Response of Voriconazole in Pediatric Patients With Invasive Aspergillosis, Invasive Candidiasis or Esophageal Candidiasis. Pediatr Infect Dis J. 2017 Jan;36(1):e1-e13. doi: 10.1097/INF.0000000000001339. PubMed 27636722 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2010, a primary completion of May 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2015, 2 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2010
First posted
Mar 25, 2010
Start
Oct 2010
Primary completionActual
May 2013
CompletionActual
Jun 2013
Results first posted
Aug 17, 2015
Last update
Jun 23, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01092832
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Mar 25, 2010
Start date
Oct 2010
Primary completion
May 2013
Completion
Jun 2013
Results posted
Aug 17, 2015
Last update
Jun 23, 2016

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Voriconazole

Start the discussion